Trial Profile
A randomised, controlled, factorial pilot study investigating Omacor [omega-3 ethylester concentrate] and/or Fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti viral therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Fluvastatin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms HCV Lipid
- 26 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2006-004335-29).
- 20 May 2010 United Kingdom Clinical Research Network has reported actual end date as 5 Nov 2009.